How Airway Stem Cell Damage Affects Chronic Lung Disease
Repeated injury to the epithelial tissue of the airways causes “biological aging” of the stem cells located there, which plays a significant role in the development of chronic lung disease.
Category: Pulmonary Fibrosis
Pulmonary Fibrosis
Latest
Pulmonary Fibrosis
Latest
Phase 3 Study Underway for Inhaled Nitric Oxide Treatment of Interstitial Lung Disease
The first patient has been enrolled in Bellerophon's Phase 3 study of pulsed inhaled nitric oxide to treat fibrotic interstitial lung disease.
Pulmonary Fibrosis
Latest
Guidance for Using High-Resolution CT for Interstitial Lung Disease
The Pulmonary Fibrosis Fdn has issued a position statement that serves as a guide for conducting high-resolution computed tomography of the thorax for interstitial lung disease.
Pamrevlumab Reduced Lung Function Decline in IPF
According to research in The Lancet Respiratory Medicine, investigational antibody pamrevlumab reduced lung function decline and slowed disease progression in patients with idiopathic pulmonary fibrosis (IPF).
Read More
Pulmonary Fibrosis Drug Development Pipeline Launched
The PF Foundation has launched a new PF Drug Development Pipeline tool to help the pulmonary fibrosis community search for different treatment options.
Read More
Idiopathic Pulmonary Fibrosis Drugs Increase Longevity, Decrease Hospitalizations
Pulmonary fibrosis drugs pirfenidone and nintedanib appear to increase longevity and decrease hospitalizations in IPF patients.
Read More
Occupational Hazards Account for More Than One in Ten People with Range of Lung Diseases
More than 1 in 10 people with a range of non-cancerous lung diseases may be sick as a result of...
Read More
PFF Patient Registry Research Generates 23 Studies
To date, 23 studies, including abstracts and manuscripts, have been developed or are underway using data from the Pulmonary Fibrosis Foundation Patient Registry.
Read More
Drug Reduced FVC Decline in Pulmonary Fibrosis Patients
A clinical study of patients with idiopathic pulmonary fibrosis treated with PRM-151 demonstrated the drug had a sustained benefit on 6-minute walking distance and on reducing FVC decline.
Read More
Trial to Test Therapy for Persistent Cough in Pulmonary Fibrosis
Respivant Sciences has dosed the first patient in the SCENIC trial, a Phase 2b study of RVT-1601 for the treatment of persistent cough in patients with idiopathic pulmonary fibrosis (IPF).
Read More
PF Foundation Reaffirms Caution Over Stem Cell Therapies for PF
The Pulmonary Fibrosis Foundation strongly cautions patients with PF against using stem cell treatments outside of an approved clinical trial.
Read More
Idiopathic Pulmonary Fibrosis Diagnostic Gets Medicare Coverage
Veracyte Inc has received a final Medicare local coverage determination (LCD) for the Envisia Genomic Classifier, a genomic diagnostic for idiopathic pulmonary fibrosis (IPF).
Read More
Mutation Prevents Mucus Clearance in Small Airways
Investigators have identified a connection between mucus in the small airways and pulmonary fibrosis.
Read More
New Resource for Pulmonary Fibrosis Patients
Responsum for PF is a free service that allows patients to easily access trusted, comprehensive, and understandable content for pulmonary fibrosis patients, families and caregivers.
Read More
Consider These Respiratory-related Charities for the Holidays
If you’re still looking for a place to give a donation this holiday season, here are just a few charitable organizations that focus on the treatment and/or research of respiratory-related diseases.
Read More